Rehovot-based NeuroDerm, which has developed a transdermal drug delivery system for the treatment of Parkinson’s disease, raised $45 million by issuing 4.5 million shares at $10 per share, giving it a company value of $164 million, after money. The amount raised could rise to $50 million, if the underwriters take...

D-Pharm Ltd (TASE: DPRM) has raised 12.8M NIS in aggregate. D-Pharm’s largest shareholder, CLAL Biotechnology (CBI), exercised all its rights to the tune of 8.7M NIS and a third of the total funds raised were from the public. D-Pharm is a clinical-stage neuroscience company focused on the development of pioneering...

Zingenix, previously known as ILIT Bio Ventures Ltd is  continuing its    development programs, focusing on gene therapy for severe orphan disorders including DMD(Ducehenne Muscular Dystrophy) ,using artificial transcription factors technologies. The company has raised a seed round of funding and has been joined by Dr. Robert Heft from Canada who has...

Compugen Ltd. (NASDAQ: CGEN) has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone relates to the second preclinical milestone...

Researchers from Israel and Jordan are seeking a treatment for cutaneous leishmaniasis in a new project, initiated by Israeli research company Pharmaseed. The project brings together a consortium of parties from Israel, Jordan, and Switzerland for the treatment of cutaneous leishmaniasis, a variant of the parasitic disease leishmaniasis, also known...